Journal of Current Medical Research and Opinion http://cmro.in/index.php/jcmro <p>&nbsp;<strong><em>Journal of Current Medical Research and Opinion</em></strong> is a&nbsp;peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies,&nbsp;and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.&nbsp;</p> <p style="text-align: justify;">The aim of <strong><em>Journal of Current Medical Research and Opinion</em></strong> is to provide ethical, unbiased and rapid publication of quality content that is validated by rigorous peer review. Journal aim is to serve the information needs of the clinical medicine community, to help translate medical advances into patient care and be a leader in transparency/disclosure by facilitating a collaborative and honest approach to publication.</p> <p style="text-align: justify;">&nbsp;</p> Journal of Current Medical Research and Opinion en-US Journal of Current Medical Research and Opinion 2589-8760 Central Line Handling Practices at Cardiac ICU of a Tertiary Care Hospital – Analysis and Learnings from an Academic Project http://cmro.in/index.php/jcmro/article/view/150 <p>Central line infections are very high and common. Nurses’ are at fore front of care after receiving surgical patients with indwelling central lines. There is a dire need to assess how these practices are happening and ongoing learning process along evaluation of practice for nurses must be maintained. Keeping a similar kind of aim an academic project was carried out in a Tertiary Care Hospital, to see how this aim can be achieved with beginning of simple strategies. However outcomes are still needed to be checked and evaluated but through ongoing monitoring process the project was seen successfully implemented. The strategies were shared and implemented in the area and the paper presents the analysis and showcasing of the action plan made and implemented. It is recommended to do this project in other areas and settings as well and the changes (decrease) in the rates of infections and practices of nurses can again be evaluated.</p> Sarmad Muhammad Soomar Khalid Ahmed Salman Ranani ##submission.copyrightStatement## http://creativecommons.org/licenses/by/4.0 2019-04-12 2019-04-12 2 04 125 128 10.15520/jcmro.v2i04.150 Giant Occipito Cervical Lipoma Case Report and Reviewof Literature http://cmro.in/index.php/jcmro/article/view/138 <p>Lipomas are benign tumors composed of adipose tissue. They are almost encountered in the shoulder, back and neck regions. Clinically, they are usually presented as asymptomatic due to their slow growth.&nbsp; Recurrence is very rare after surgical resection.</p> <p>Giant lipoma in the cervical region israre and thus requiring surgical excision is for esthetic reasons, pain and limitation of neck mobility or problems in daily living.</p> <p>Some of these giant lipomas may become malignant and deteriorate quality of life.</p> <p>In the present study, we report a case of giant lipoma of the neck which was treated surgically with excellent outcome.</p> M.Bouallag, N.Habchi, H.Bekralas, W.Boulaouad, R. Oumchiche, M.DJaafer ##submission.copyrightStatement## http://creativecommons.org/licenses/by/4.0 2019-04-12 2019-04-12 2 04 129 132 10.15520/jcmro.v2i04.138 Safety and Efficacy of Fulranumab in Osteoarthritis of the Hip and Knee: Results From Four Randomized, Double-blind, Placebo-controlled Phase III Studies http://cmro.in/index.php/jcmro/article/view/144 <p><strong>Purpose:</strong> To evaluate the safety and efficacy of fulranumab as adjunct or monotherapy in patients with knee or hip pain related to moderate-to-severe osteoarthritis.</p> <p><strong>Methods: </strong>Osteoarthritic patients (aged ≥18 years) from 4 phase 3 randomized, double-blind (DB), placebo-controlled studies were randomized to receive placebo, fulranumab 1 mg every 4 weeks (Q4wk), or 3 mg Q4wk in 16-week DB phase, followed by a 52-week post-treatment follow-up phase. Safety assessments included treatment-emergent adverse events (TEAEs), and neurological, sympathetic and joint-related events of interest. Efficacy assessments included pain and physical function subscales of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores.</p> <p><strong>Findings: </strong>Of 245 patients from the ITT set (median age, 64 years; women, 62%), 84 (34%) completed DB phase; the majority of discontinuations (57%) were due to early study termination. In DB phase, incidence of TEAEs in fulranumab 3 mg (57.8%) and 1 mg (56.8%) was similar to placebo (56.8%). Two events adjudicated as joint-related events of interest include rapidly progressive osteoarthritis and fracture of unknown etiology. There were no new neurological TEAEs. Fulranumab showed evidence of efficacy in improving pain and physical function based on WOMAC subscales scores. Due to premature study termination, the number of patients enrolled were too small to make any definitive efficacy claims.</p> <p><strong>Implications:</strong> Treatment with fulranumab was generally tolerated with no new safety signals. Within the limited sample analyzed, fulranumab showed evidence of improvement of pain and function in patients with moderate-to-severe osteoarthritis who had failed prior therapy and were candidates for joint replacement surgery.</p> <p><strong>Clinical trial registration numbers:</strong> NCT02336685, NCT02336698, NCT02289716, NCT02301234</p> Kathleen M Kelly Panna Sanga Naim Zaki Steven Wang Juergen Haeussler John Louie John Thipphawong ##submission.copyrightStatement## http://creativecommons.org/licenses/by/4.0 2019-04-12 2019-04-12 2 04 133 143 10.15520/jcmro.v2i04.144